Title: Chief Scientific Officer
Company: Endolytix Technology Inc.
Location: Swampscott, Massachusetts, United States
Jason Wyatt Holder, chief scientific officer at Endolytix Technology Inc., has been recognized by Marquis Who’s Who Top Scientists for dedication, achievements, and leadership in scientific research and pharmaceuticals.
With over three decades of experience, Mr. Holder has built a successful career in scientific research and pharmaceuticals. He currently serves as co-founder and chief science officer at Endolytix, a role he has held since 2020. His experience includes principal member of the technical staff at Draper from 2015 to 2019, group leader at Draper from 2016 to 2017, and synthetic molecular engineer at The Charles Stark Draper Laboratory from 2015 to 2019. He also founded Pharogen Inc., where he served as chief science officer from 2014 to 2015, and worked as a contract research scientist at The Broad Institute from 2013 to 2014. Earlier in his career, he was a senior scientist at Sample6 Technologies from 2011 to 2013, a visiting scientist at The Broad Institute from 2008 to 2011, and a research technician at Johns Hopkins School of Medicine from 1995 to 1998. He also interned at Washington University School of Medicine from 1992 to 1993.
Mr. Holder has contributed to the field through his co-authorship of significant publications, including “Comparative Genomic Analysis of Human Fungal Pathogens Causing Paracoccidioidomycosis” and “Comparative and Functional Genomics of Rhodococcus opacus PD630 for Biofuels Development” in PLoS Genetics (2011), “Architecture of the Tn7 post-transposition complex” in J Mol Biol (2010), and key articles in The Journal of Cell Biology in 2000 and 1997. Additionally, he holds patents for recombinant phage and bacterial detection methods. In light of his impressive undertakings, he was awarded the Cambridge MIT Partnership Program Exchange Grant from the Massachusetts Institute of Technology in 2008, the MITEI Seed Grant from the MIT Energy Initiative in 2008, and the Howard Hughes Summer Internship from the Howard Hughes Medical Institute in 1994. Laying a solid educational foundation for his successes, he earned a Bachelor of Science in microbiology from Indiana University Bloomington in 1995, followed by a PhD in biochemistry, cell, and molecular biology from Johns Hopkins University School of Medicine in 2006, and a postdoctoral fellowship in genomics and metabolic engineering at MIT in 2011. He attributes his success to the invaluable guidance of his mentors. In the coming years, he aims to introduce new drugs and treatment methods to the market, particularly focusing on curing both tuberculosis and non-tuberculosis bacterial infections.
For more information, please visit:
Contact Mr. Holder:
